In early October of 2011, the U.S. Preventive Services Task Force (USPSTF) released a draft report in which they recommended against using the prostate-specific antigen (PSA) test to screen for prostate cancer. The resulting furor, fueled by presidential candidates, spokespersons for advocacy organizations, and prostate-cancer survivors, involved a number of serious misunderstandings. This episode closely resembled the situation in 1997, when the National Institutes of Health (NIH) Consensus Development Conference concluded that women ages 40 to 49 should decide for themselves whether to get mammograms (NIH Consensus Development Panel, 1997). This recommendation contradicted the prevailing view of many organizations—that mammograms should be routinely given to women in this age group. Both the PSA and the mammogram controversies engendered rancorous “discussion” punctuated by denigrating personal attacks on the panel members by politicians and other individuals.

Our goal here is to examine the PSA testing controversy from the perspective of psychologists who do research in the area of judgment and decision making. We hope to resolve this paradox: How can the personal experience of some people be so contrary to the scientific evidence that motivated the panel’s recommendations? A secondary goal is to provide some guidance to future panels so that they might be able to communicate their science-based recommendations more successfully.

PSA Screening: Some Background and Clinical Evidence

We begin by very briefly outlining the goals of PSA screening and the bases for the USPSTF report.

First, it is important to understand that the goal of all cancer screening methods is not simply the early detection of disease. Rather, screening is aimed at reducing mortality or improving quality of life. Screening is targeted at people without symptoms, to test for hidden disease. To be useful, early detection needs to enable earlier treatment that is either more effective or safer than later treatment.

Second, it is important to understand that medical treatments usually both have benefits and cause harm, and this is also true for cancer screening. Although the principal alleged benefit of PSA screening—the reduction of prostate-cancer mortality—is relatively obvious, the harms associated with treatment are more subtle. The most important harm is overdiagnosis, which can eventually lead to overtreatment. Overdiagnosis is defined as the detection of an abnormality that
would never progress to cause problems in a patient’s lifetime, such as a nonprogressive prostate cancer. Treating a nonprogres-
sive prostate cancer is obviously not beneficial, and it can
even be harmful and cause impotence or incontinence as a side
effect. In addition to conveying the risk of overdagnosis and
over treatment, participation in screening bears the risk of
yielding false-positive test results that can lead to psychological
distress and unnecessary biopsies.

The USPSTF based its conclusion on the best available sci-
entific evidence about the benefits and harms of PSA screen-
ing. We highlight the central facts here. In a recent large
clinical trial, it was demonstrated that over a period of 9 years,
out of every 1,410 men who regularly participated in prostate-
cancer screening, there was 1 fewer death due to prostate
cancer compared with an equally large group of men who did not
participate in screening (Schröder et al., 2009). Additionally,
the comparison with men who did not participate in screening
revealed that 48 out of the 1,410 men who regularly partici-
pated in prostate-cancer screening were unnecessarily treated
(i.e., without receiving a benefit such as increased longevity)
and hence subjected to risks such as incontinence and impo-
tence. Furthermore, in this study, PSA screening did not reduce
overall mortality at all. That is, the slight reduction in mortal-
ity due to prostate cancer was balanced out by a slight increase
in mortality due to other causes. Also, a second large clinical
trial, reported in the same issue of the same medical journal,
found no reduction in prostate-cancer mortality through
screening (Andriole et al., 2009). More recently, two meta-
analyses summarizing the best available evidence on PSA
screening concluded that there is currently no indication that it
is effective in reducing mortality (Djulbegovic et al., 2010; Illic, O’Connor, Green, & Wilt, 2011). Also, a 20-year follow-
up did not find a benefit of PSA screening, whereas the harms,
such as unnecessary treatments, are unquestioned (Sandblom,

We turn now to the factors that we hypothesize made the
expression of these facts in the USPSTF report so controversial.

**Factor 1: The Power of the Anecdote**

Several studies have shown that an anecdote or two can have a
more powerful effect on decision making than a compendium of
more reliable statistical data (de Wit, Das, & Vet, 2008; Fagerlin, Wang, & Ubel, 2005; Hamill, Wilson, & Nisbett,
1980; Ubel, Jepson, & Baron, 2001). For example, Fagerlin et
al. (2005) presented people with statistics indicating that
bypass surgery had a 75% cure rate for angina, and balloon
angioplasty had a 50% cure rate. All participants also read
anecdotes purportedly written by persons who had successful
or unsuccessful outcomes of one of the treatments. For half of
the participants, the proportion of successful-treatment anec-
dotes was representative of the actual base rates of success
(i.e., 75% for bypass surgery and 50% for angioplasty). The
other half of the participants read anecdotes that contained
equal numbers of successful and unsuccessful outcomes for
each treatment. Thus, for these participants, the frequency of
the successful and unsuccessful anecdotal outcomes was not
representative of the statistics for surgery. When participants
were asked to choose which treatment they would prefer, the
percentage of the representative-anecdote group who chose
bypass surgery was more than twice the percentage of the
unrepresentative-anecdote group who chose that surgery (41%
vs. 20%). The anecdotes thus had a substantial influence on
treatment choice, even though identical statistical data were
presented to the two groups. Public comments on the USPSTF
Web site are replete with just such anecdotes. These members
of the public were not persuaded by the statistical data but
were convinced by the case of an individual they knew. This
same type of anecdotal analysis was used by several U.S. poli-
ticians, such as former New York City Mayor Rudy Giuliani
(Campanile, 2011) and U.S. Congress member Donna Chris-
tensen (2011).

Closely related to the power of the anecdote is the
identifiable-victim effect, which is defined as the willingness
“to expend greater resources to save the lives of identified vic-
tims than to save equal numbers of unidentified or statistical
victims” (Jenni & Loewenstein, 1997, p. 235). Charities often
utilize this principle by highlighting an individual “poster
child” or by pairing a potential donor with one potential recipi-
ent of the donor’s largesse. Statistical lives tend to elicit
weaker reactions than specific, individual lives. In fact, Slovic
(2007) has shown that people who are informed about a large
number of statistical victims tend to experience psychological
numbness, rather than enhanced concern. Surprisingly, this
identifiable-victim effect can be observed even when the com-
parison is between one victim and a group of as few as eight
victims (Kogut & Ritov, 2005).

When a reader of the USPSTF report tries to digest the
information about statistical lives, this information does not
have the same impact as information, say, about the reader’s
mail carrier’s older brother who had a positive PSA test, a
biopsy, and a radical prostatectomy, and is now still alive. The
information that “no trial has shown a decrease in overall mor-
tality with the use of PSA-based screening through 11 years of
followup” (USPSTF, 2011, first sentence in the section “Esti-
mate of Magnitude of Net Benefit”) will not have the same
probative value as awareness of a putative identified benefi-
ciary of the PSA test. Thus, such anecdotes may contribute to
the widespread gross overestimation of the benefits of PSA
screening (Gigerenzer, Mata, & Frank, 2009).

**Factor 2: Epidemiology Versus
Personal Experience**

Consider two auditoriums, each of which contains 1,000 men
age 50 or older. Auditorium “Screened” contains 1,000 men
who have had a PSA screening test. Auditorium “Not
Screened” contains 1,000 men who have not had such a test.
About 8 men from each auditorium will die from prostate

cancer in the next 10 years (Djulbegovic et al., 2010). A very
important conclusion to be drawn from these numbers is that screening does not decrease prostate-cancer mortality. How can this be, given that so many men claim to have been saved by a PSA test?

Let us take a look at three possible subgroups of men in Auditorium Screened. These three subgroups have in common that they received a positive PSA test result. The first group consists of those men whose positive PSA test actually did detect a progressive prostate cancer and who are still alive because their cancer was detected early and subsequently treated successfully. This group’s members rightfully believe that they were saved by a PSA test. However, given that the USPSTF report and some of the meta-analyses cited earlier raise doubt that PSA screening does in fact reduce prostate-cancer mortality (not to speak of overall mortality), it is unclear whether there actually are such men in the auditorium. Even in light of the more favorable trials, such as the European Randomized Study of Screening for Prostate Cancer (Schröder et al., 2009) and its recent update (Schröder et al., 2012), it seems safe to assume that PSA screening saved at most 1 man in the auditorium from dying from prostate cancer; and in light of the less favorable evidence (Andriole et al., 2009; Djulbegovic et al., 2010; Ilic et al., 2011; Sandblom et al., 2011), quite possibly none have been saved.

The second group in Auditorium Screened consists of about 20 men who were unnecessarily diagnosed and treated, because their cancers would have never caused them harm had the cancers not been detected by screening (Djulbegovic et al., 2010). Quite a few of these men will have serious side effects, such as impotence or incontinence, as a consequence of the treatment. About a quarter of the men who have a radical prostatectomy will have such symptoms (USPSTF, 2011). Elevated risks of impotence and bowel dysfunction follow radiation treatment, too. Thus, in this subgroup of 20 men, there will be about 5 who will have to live with such consequences, which they would not have experienced had they not undergone treatment. Moreover, these men faced a small risk of dying from the surgery: About 5 out of every 1,000 men (which equals 0.1 in this subgroup of 20 men) will die within 30 days of undergoing a radical prostatectomy. Yet these 20 men do not know that the screening did not improve their eventual outcome, so they mistakenly believe that they were saved by the PSA test. Even those with serious side effects will probably believe that the side effects are worth it, even though the screening, with subsequent treatment, only caused them harm with no benefit. Thus, they are angry about the task force’s recommendation to forgo the PSA test. Their families also think that the prostate cancer is the reason why they had to undergo treatment, and do not know that the treatments were actually unnecessary and only harmful. These families might be very unhappy with the PSA screening test if they did know.

Auditorium Screened also contains a third group of about 180 men who received a false-positive test result and had an unnecessary biopsy. Even if a man has only a biopsy with no further medical treatment, there is the risk of harm. Seven percent of the men who have prostate biopsies (i.e., 12.6 of these 180) have to be hospitalized because of infections and other complications (Loeb, Carter, Berndt, Ricker, & Schaeffer, 2011). These 180 men will probably not think that they have been saved, but will be relieved that their test result was only a false alarm. Probably only few of them, if any, will blame the test, however, for having produced a false alarm in the first place.

So, in Auditorium Screened, there are a lot of men who think that the PSA screening provided more benefit than harm, when in fact the opposite is true. We know that it is true because (a) the number of prostate-cancer deaths is the same in the two auditoriums, but (b) Auditorium Screened contains many men with serious side effects that could have been avoided had the men not been screened with a test that has a high false-positive rate.

We cannot blame the men in Auditorium Screened for their beliefs that they are healthier than the men in Auditorium Not Screened and that death from prostate cancer has reduced their numbers to a lesser degree. In the real world, there are no such adjacent auditoriums whose proximity allows an easy comparison of the health status of the two groups. Of course, epidemiological studies allow for such comparisons. When the men in Auditorium Screened rely on their personal experience, they are not aware of the counterfactuals. They do not know about the fate of the men who were not screened or of the men who made different treatment choices than they did. An individual man might only know that he was screened, had a biopsy, was treated, and now does not have prostate cancer. He thinks the PSA test saved his life, and he places an unkind comment about the task force members’ professional competence on USPSTF’s Web site.

What if there were adjacent auditoriums, one containing men who had been screened and one containing men who had not been screened? Even under such ideal circumstances allowing for straightforward comparison of outcomes, the research we describe next (in discussing Factor 3) suggests that men in Auditorium Screened still might evaluate such data improperly.

Before turning to Factor 3, we briefly add two caveats about our example of the two auditoriums. First, in the United States, the majority of men above the age of 50 have had a PSA test (Ross, Berkowitz, & Ekwueme, 2008). Indeed, 95% of male urologists and 78% of male primary-care physicians age 50 and older have had a PSA test (Chan, Barry, Vernon, & Ahn, 2006). Contrary to our example, the number of men in U.S. Auditorium Screened is in fact much larger than the number in U.S. Auditorium Not Screened. Thus, the relative number of men whose PSA screening has led to more harm than benefit is actually larger than our example suggests. Second, we have used averages in our calculations, so the numbers might vary depending on such factors as whether any subgroups of men have particular risk factors, such as a family history of prostate cancer.
Factor 3: Improper Data Evaluation

Consider the $2 \times 2$ matrix depicted in Figure 1. In evaluating the relation between the PSA test and mortality, laypersons generally pay the most attention to the data in cell A, and they pay more attention to the data in the top row than to the data in the bottom row (Arkes & Harkness, 1983; Shaklee & Tucker, 1980; Ward & Jenkins, 1965). This implies that people’s evaluation of the PSA test would be most influenced by the large number of men they know who have gotten a PSA test and who are still alive. These men are in cell A, whose data contribute to the conclusion that the test is beneficial. This positive view of the PSA test is exacerbated by the fact that most men who receive PSA screening do not realize that their outcome would have been the same had they not been screened.

In other words, the proportion of the data in the top row that belongs in cell A is nearly identical to the proportion of the data in the bottom row that belongs in cell C; the overall mortality rates for screened and not-screened men is the same (Schröder et al., 2009, 2012). All four cells of Figure 1 are needed to ascertain whether screening is more effective than no screening with regard to mortality. Although research results suggest that many people do not think the evidence in cells C and D is important in evaluating the effectiveness of the PSA test (e.g., Arkes & Harkness, 1983), the people on the USPSTF think that this evidence is highly relevant. The people on the task force know that cells C and D comprise the control group’s data. Many laypersons do not understand that a control group is needed in order to evaluate the effectiveness of a medical intervention or test. By attending primarily to cell A and by giving insufficient attention to cells C and D, many members of the general public will not comprehend a central basis for the task force’s negative opinion of the PSA test.

Factor 4: Screening Tests for Low-Base-Rate Events

Meehl and Rosen (1955) pointed out long ago that screening tests that are highly informative for a select subgroup are not necessarily well suited for screening the general population.

With a cutoff point of 4 ng/ml, the PSA test is reported to have a sensitivity of approximately 21% and a specificity of approximately 94% (Thompson et al., 2005). That means the PSA test will correctly classify 21% of the men with prostate cancer and 94% of the men who do not have prostate cancer. Conversely, the test will miss about 79% of the men who actually have prostate cancer, and raise a false alarm in 6% of the men who actually do not have prostate cancer. Suppose that this test is given to 1,000 patients at a urology clinic who have symptoms diagnostic of prostate cancer. Perhaps 50% of these men truly have prostate cancer. Table 1 depicts this situation. Of the 135 men who test positive, 105 actually have prostate cancer. Thus, the positive predictive value of the PSA test in this situation is approximately 78% (i.e., $105/(105 + 30) \times 100$).

Now let us consider using the same screening test when prostate cancer is a low-base-rate event. If the test is used to screen the general population of males, the base rate will be much lower than the 50% depicted in Table 1. In one of the largest studies of prostate-cancer screening (Schröder et al., 2009), the base rate of prostate cancer was only 6.3%. Table 2 depicts this low-base-rate situation. Now the positive predictive value is down to 19%. This means that 81% of the positive test results are false positives! Many of the men with these positive test results will have biopsies with associated morbidity (Loeb et al., 2011). Some of these men will have prostatectomies, radiation therapy, or hormone therapy with their associated morbidities (Chou et al., 2011). The problem is that a test with modest sensitivity or specificity is not appropriate for screening the general population unless the cost of false positives or false negatives is very low.
Prophylactic Measures

One of us has served on government committees whose reports are not welcomed (Arkes, 2003). In part on the basis of that experience, we suggest using what has been learned from psychological research to help such committees communicate more successfully with the public and the U.S. Congress.

One way of effectively communicating clinical evidence to the public is to use facts boxes, which are simple tabular representations of the benefits and harms of particular treatments. Schwartz, Woloshin, and Welch (2007, 2009) developed the concept of drug facts boxes and successfully tested their use with laypeople. Inspired by Woloshin and Schwartz (2009), the Harding Center for Risk Literacy at the Max Planck Institute for Human Development has designed a facts box about the benefits and harms of PSA screening (Fig. 2).

Another very effective means of informing the public about clinical evidence is to use visual displays. Let us consider again the study by Fagerlin et al. (2005). In addition to the groups we have already described, other groups of subjects saw the base rates of success of bypass surgery and angioplasty depicted with pictographs. Thus, for angioplasty, a matrix of 100 small figures was presented, with half of them colored to represent those cured of angina. For bypass surgery, the matrix had 75 figures colored to represent those cured of angina. For these two groups of subjects, the differing proportions of anecdotal successful and unsuccessful outcomes did not have a significant influence on treatment choices. Several other studies suggest that such pictorial depictions significantly increase understanding of statistical data and counteract the influence of anecdotal data (Fischhoff, Brewer, & Downs, 2011; Hawley et al., 2008).

1 We suggest that the USPSTF report would have been more successfully understood had such pictorial representations been used. In its current form, the report contains a very large number of statistics, which will overwhelm the general public. Research has shown that numeracy among the American public is shockingly low (Galesic & Garcia-Retamero, 2010; Lipkus, Samsa, & Rimer, 2001; Schwartz, Woloshin, Black, & Welch, 1997; Woloshin, Schwartz, & Welch, 2005). Pictorial representations help, and Figure 3 illustrates what an icon array for PSA screening could look like.

It is instructive that the public reaction to the USPSTF report can be understood in part by referring to psychological research. It would be particularly helpful if such research could be used to educate the public and elevate the level of civic discussion.

**Fig. 2.** Facts box illustrating the benefits (or lack thereof) and harms of prostate-specific antigen (PSA) screening for men age 50 and older. The underlying epidemiological data are taken from Djulbegovic et al. (2010). Note that the numbers are not meant to be the final verdict on PSA screening, but rather serve to illustrate the order of magnitude of the effects. Copyright 2012 by the Harding Center for Risk Literacy.
Acknowledgments
We thank Birgit Silberhorn and the members of the Harding Center for Risk Literacy for their help with the facts box and the icon array.

Declaration of Conflicting Interests
The authors declared that they had no conflicts of interest with respect to their authorship or the publication of this article.

Note
1. Pictographs additionally reduce several other biases, such as denominator neglect (Garcia-Retamero, Galesic, & Gigerenzer, 2010), duration neglect (Liersch & McKenzie, 2009), and framing effects (Garcia-Retamero & Cokely, 2011; Garcia-Retamero & Galesic, 2010).

References


---

Prostate Cancer Early Detection
by PSA screening and digital-rectal examination.
Numbers are for men aged 50 years or older, not participating vs. participating in screening for 10 years.

1,000 men without screening:
- Men dying from prostate cancer: 8
- Men dying from any cause: 200
- Men that were diagnosed and treated for prostate cancer unnecessarily: –
- Men without cancer that got a false alarm and a biopsy: –
- Men that are unharmed and alive: 800

1,000 men with screening:
- Men dying from prostate cancer: 8
- Men dying from any cause: 200
- Men that were diagnosed and treated for prostate cancer unnecessarily: 20
- Men without cancer that got a false alarm and a biopsy: 180
- Men that are unharmed and alive: 600

Fig. 3. Icon array illustrating the benefits (or lack thereof) and harms of prostate-specific antigen (PSA) screening for men age 50 and older. The underlying epidemiological data are taken from Djulbegovic et al. (2010). Note that the numbers are not meant to be the final verdict on PSA screening, but rather serve to illustrate the order of magnitude of the effects. Copyright 2012 by the Harding Center for Risk Literacy.


